Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2761)	1/31/2001 10:57:29 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

Here is a link to some of the conferences: vcall.com I believe this is some of the comments on Novoste from USPJ: Reported Q4 positive results. The expected approval of the 40 mm source train in February offers the potential for off-label use on longer lesions, which could provide upside surprise to our FY01 loss of $1.82 on revenue of $37 mln. Maintain $41 target. Bernard

To: Biomaven who wrote (2761)	2/1/2001 9:08:43 PM
From: Oak Tree	Read Replies (1) \| Respond to of 52153

"So IMO the radiation stents will have a short (few-year) window that will then slam shut." I think that radiation will still be needed since I have less confidence in the drug coatings. However, regarding stock value -- I think the majority of investors favor your hypothesis and will flock to the drug coated stents. Hence if you are a doctor -- you will be able to make a career in the radiation -- if you are an investor sell short on NOVT if you are sure that they are not going to be bought out.